ddCTP trilithium is a type of chain-terminating deoxynucleotide. ddCTP trilithium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP trilithium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP trilithium is the active metabolite of Zalcitabine ( HY-17392 ), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication.
Products | Products > Disease Areas > Infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > Nucleoside Antimetabolite/Analog | Products > Signaling Pathways > HIV | Products > Signaling Pathways > Drug Metabolite | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > HIV Protease
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.